News Archive

Following a national search, the Duke Clinical Research Institute (DCRI) named new leadership for its Data Science and Biostatistics team.

Over the last 20 years, the portfolio of active industry and government research grants to a core group of pediatrics faculty working in the Duke Clinical Research Institute has grown from $5 milli

Each year, hackers steal thousands of medical records from hospitals and health organizations. Health systems face elevated threats from cyberattacks. A new perspective piece written by Duke Clinical Research Institute Chief Science and Digital Officer Eric Perakslis, PhD, and published in the New England Journal of Medicine (NEJM) offers a clinicians’ guide to cybersecurity. In “Responding to the Escalating Cybersecurity Threat in Health Care,” Perakslis offers actionable insights to help health care providers protect themselves and their patients from the threats of cyberattacks.

New research shows COVID-19 patients have a higher likelihood of heart failure post-discharge

Pulmonary rehabilitation is an important evidenced-based treatment to improve health and quality of life for people living with Chronic Obstructive Pulmonary Disease (COPD). Now, new research from the Duke Clinical Research Institute has shown that the benefits of pulmonary rehabilitation are likely to extend beyond the patient to reduce costs for the health care system as well – with an estimated savings of more than $5,000 per patient.

A special series of articles addressing pragmatic and virtual trials appears this week in the journal Contemporary Clinical Trials and offers practical approaches to the many challenges clinical trials face. The 14 articles bring together leaders, researchers, biostatisticians, and bioethicists—including members of the NIH Pragmatic Trials Collaboratory — who are rethinking key aspects of the development, conduct, and oversight of clinical trials.

If you want to change patient and provider behavior to improve a patient’s health, will an informational mailer make a difference?

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health with support from the Duke Clinical Research Institute shows that treating adults hospitalized with COVID-19 with infliximab or abatacept – drugs widely used to treat certain autoimmune diseases – substantially improved clinical status and reduced deaths.

A recent paper from Duke Clinical Research Institute (DCRI) faculty on behalf of the American Gastroenterological Association (AGA) provides new tools for health care providers treating patients wi

As the Duke Clinical Research Institute (DCRI) celebrates Clinical Trials Day and we progress into the third year of the COVID-19 pandemic, we